Art
J-GLOBAL ID：201602253718072358
Reference number：16A0659883
Successful ethinylestradiol therapy for a metastatic breast cancer patient with heavily pre-treated with endocrine therapies
内分泌療法により強く前治療されていた転移乳癌患者に対するエチニルエストラジオール治療の成功
Author (7)：
,
,
,
,
,
,
Material：
Volume：
5
Issue：
3
Page：
126-130 (WEB ONLY)
Publication year：
Jul. 2016
JST Material Number：
U0703A
ISSN：
2192-3183
Document type：
Article
Article type：
原著論文
Country of issue：
Germany, Federal Republic of (DEU)
Language：
ENGLISH (EN)
Thesaurus term：
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
Semi thesaurus term：
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
JST classification (2)：
JST classification
Category name(code) classified by JST.
Drug therapy(=pharmacotherapy)for tumors
, Clinical application of antitumor(=antineoplastic)drugs
Substance index (4)：
Substance index
Chemical Substance indexed to the Article.
,
,
,
Reference (13)：
-
Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247-2258. doi:10.1002/1097-0142(20011101)92:9<2247:AIDCNCR1570>3.0.CO;2-Y
-
Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98(18):1285-1291. doi:10.1093/jnci/djj357
-
Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664-1670. doi:10.1200/JCO.2007.13.5822
-
Di Leo A, Jerusalem G, Petruzelka L et al (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106(1):djt337. doi:10.1093/ jnci/djt337
-
Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989-998. doi:10.1016/S1470- 2045(13)70322-X
ｍore...
Terms in the title (6)：
Terms in the title
Keywords automatically extracted from the title.
,
,
,
,
,
Return to Previous Page
